Dysphonia News and Research

RSS

Vagus nerve dysfunction has a central pathogenic role in the pathophysiology of the post-COVID condition

Researchers studied if vagus nerve dysfunction has a central pathogenic role in the pathophysiology of the post-COVID condition.

21 Jun 2023

Study points to vagus nerve dysfunction as a central pathophysiological feature of long COVID

New research to be presented at this year's European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April) suggests that many of the symptoms connected to post-COVID syndrome (PCC, also known as long COVID) could be linked to the effect of the virus on the vagus nerve – one of the most important multi-functional nerves in the body.

12 Feb 2022

Mass Eye and Ear researcher receives P50 NIH grant to establish new center for neurological voice disorders

Kristina Simonyan, MD, PhD, Dr med, director of laryngology research at Mass Eye and Ear, has been awarded an $11.9 million P50 Clinical Research Center Grant from the National Institute on Deafness and Other Communicable Disorders of the National Institute of Health to form a new multidisciplinary center across four academic medical institutions that will be committed to conducting research on laryngeal dystonia and voice tremor, two debilitating neurological voice disorders.

28 Sep 2021

FDA approves drug-free stroke rehabilitation system to treat upper extremity motor deficits

The U.S. Food and Drug Administration today approved the MicroTransponder Vivistim Paired VNS System (Vivistim System), a first-of-its-kind, drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms—using vagus nerve stimulation (VNS).

27 Aug 2021

Researchers develop unique diagnostic tool to detect dystonia from MRI scans

Researchers at Mass Eye and Ear have developed a unique diagnostic tool that can detect dystonia from MRI scans, the first technology of its kind to provide an objective diagnosis of the disorder.

29 Sep 2020

MiRus announces FDA clearance of CYGNUS Anterior Cervical Plate System

MiRus is pleased to announce recent FDA 510(k) clearance of the CYGNUS™ Anterior Cervical Plate System, the narrowest and thinnest cervical plate on the market.

27 Jul 2019

Stress may cause vocal disorders

Do you feel anxious about talking in front of the crowd and feel as if there’s a frog in your throat? New reseach says that stress may be the culprit for such vocal issues.

25 Jul 2019

Study explores impact of voice disorders ad listener strategies on speech intelligibility

"Fly heading two three zero, runway two seven left, cleared for takeoff." Air traffic controllers are among the 25 to 45 percent of the workforce in the United States who use their voices professionally. It is imperative for their listeners to understand what they are communicating.

16 May 2019

FDA approves first generic version of commonly prescribed asthma inhaler

The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

30 Jan 2019

MUSC researchers uncover a new cause for laryngeal symptoms

While a sudden coughing fit is a protective reflex to clear the airway, chronic cough can be caused by multiple factors that must be investigated to determine treatment. Cough is just one of several laryngeal symptoms including hoarseness and dysphoric breathing that can become debilitating.

4 Jan 2019

FOTIVDA expected to be included in new ESMO guidelines for advanced renal cell carcinoma

EUSA Pharma welcomes the news that FOTIVDA (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology clinical practice guidelines for advanced renal cell carcinoma, anticipated to be published at the end of this year.

22 Oct 2018

FDA approves new drug for treatment of lung disease caused by Mycobacterium avium complex

The U.S. Food and Drug Administration today approved a new drug, Arikayce, for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex in a limited population of patients with the disease who do not respond to conventional treatment.

29 Sep 2018

Stivarga receives expanded FDA approval for treatment of liver cancer

The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafinib) to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib.

28 Apr 2017

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress.

4 May 2016

Cerebellar not cerebral atrophy predicts poor anti-NMDAR encephalitis outcome

Diffuse cerebral atrophy in patients with anti-N-methyl-D-aspartate receptor encephalitis does not necessarily mean irreversible brain damage, whereas progressive cerebellar atrophy may indicate a poor long-term prognosis, researchers report.

4 May 2016

FDA accepts Allergan's resubmission of BOTOX sBLA for treatment of adults with upper limb spasticity

Allergan plc, a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration has accepted the company's resubmission of its Supplemental Biologics License Application (sBLA) for BOTOX (onabotulinumtoxinA) for the treatment of adults with lower limb (involving ankle and toe muscles) spasticity in adults.

20 Aug 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

New device to monitor voice professionals and track vocal changes

A new device to monitor voice professionals as well as to track vocal changes that are due to chronic diseases and physical or psychological stress

8 May 2014

Bayer enrolls patients for Phase III trial of Stivarga (regorafenib) tablets in colorectal cancer

Bayer HealthCare today announced that the company has begun to enroll patients in the COAST trial studying Stivarga® (regorafenib) tablets in colorectal cancer (CRC) patients with resected liver metastases.

20 Feb 2014